Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Prevalence of fat-soluble vitamin (A, D, and E) and zinc deficiency in patients with cirrhosis being assessed for liver transplantation.

Teriaky A, Mosli M, Chandok N, Al-Judaibi B, Marotta P, Qumosani K.

Acta Gastroenterol Belg. 2017 Apr-Jun;80(2):237-241.

PMID:
29560688
2.

Primary sclerosing cholangitis: diagnostic and management challenges.

Sirpal S, Chandok N.

Clin Exp Gastroenterol. 2017 Nov 6;10:265-273. doi: 10.2147/CEG.S105872. eCollection 2017. Review.

3.

Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients.

Uhanova J, Minuk G, Lopez Ficher F, Chandok N.

Can J Gastroenterol Hepatol. 2016;2016:6420408. doi: 10.1155/2016/6420408. Epub 2016 Apr 28.

4.

When to perform gastroscopy in the PSC patient.

Tse Y, Narula N, Uhanova J, Sirpal S, Marotta P, Chandok N.

Ann Hepatol. 2016 Jan-Feb;15(1):135-6. No abstract available.

5.

Transient elastography in Canada: current state and future directions.

Aljawad M, Sirpal S, Yoshida EM, Chandok N.

Can J Gastroenterol Hepatol. 2015 Oct;29(7):373-6. Epub 2015 Jun 12.

6.

Duct-to-Duct Biliary Anastomosis Yields Similar Outcomes to Roux-en-Y Hepaticojejunostomy in Liver Transplantation for Primary Sclerosing Cholangitis.

Al-Judaibi B, Hernandez Alejandro R, Uhanova J, Marotta P, Mosli M, Chandok N.

Hepat Mon. 2015 May 23;15(5):e18811. doi: 10.5812/hepatmon.15(5)2015.18811. eCollection 2015 May.

7.

An elderly lady with significant weight loss.

Al-Judaibi B, Driman DK, Chandok N.

Arab J Gastroenterol. 2015 Mar;16(1):31-2. doi: 10.1016/j.ajg.2014.10.003. Epub 2015 Mar 14.

PMID:
25784461
8.

The trientine crisis in Canada: a call to advocacy.

Chandok N, Roberts EA.

Can J Gastroenterol Hepatol. 2014 Apr;28(4):184. No abstract available.

9.

Out with the old and in with the new: hepatic fibrosis assessment in Canada.

Chandok N.

Can J Gastroenterol Hepatol. 2014 Jan;28(1):20. No abstract available.

10.

Comparing outcomes of donation after cardiac death versus donation after brain death in liver transplant recipients with hepatitis C: a systematic review and meta-analysis.

Wells M, Croome KM, Janik T, Hernandez-Alejandro RM, Chandok NM.

Can J Gastroenterol Hepatol. 2014 Feb;28(2):103-8. Epub 2013 Nov 28. Review.

11.

Percutaneous liver biopsy practice patterns among Canadian hepatologists.

Aljawad M, Yoshida EM, Uhanova J, Marotta P, Chandok N.

Can J Gastroenterol. 2013 Nov;27(11):e31-4.

12.

Female donor to male recipient gender discordance results in inferior graft survival: a prospective study of 1,042 liver transplants.

Croome KP, Segal D, Hernandez-Alejandro R, Adams PC, Thomson A, Chandok N.

J Hepatobiliary Pancreat Sci. 2014 Apr;21(4):269-74. doi: 10.1002/jhbp.40. Epub 2013 Sep 30.

PMID:
24123790
13.

Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review.

Wells MM, Roth LS, Marotta P, Levstik M, Mason AL, Bain VG, Chandok N, Aljudaibi BM.

Saudi J Gastroenterol. 2013 Sep-Oct;19(5):223-9. doi: 10.4103/1319-3767.118133.

14.

Liver transplantation for alcoholic liver disease among Canadian transplant centres: a national study.

Chandok N, Aljawad M, White A, Hernandez-Alejandro R, Marotta P, Yoshida EM.

Can J Gastroenterol. 2013 Nov;27(11):643-6. Epub 2013 Sep 13.

15.

Roux-en-Y choledochojejunostomy versus duct-to-duct biliary anastomosis in liver transplantation for primary sclerosing cholangitis: a meta-analysis.

Wells MM, Croome KP, Boyce E, Chandok N.

Transplant Proc. 2013 Jul-Aug;45(6):2263-71. doi: 10.1016/j.transproceed.2013.01.066. Review.

PMID:
23953538
16.

The effect of liver transplantation for primary sclerosing cholangitis on disease activity in patients with inflammatory bowel disease.

Mosli M, Croome K, Qumosani K, Al-Judaibi B, Beaton M, Marotta P, Chandok N.

Gastroenterol Hepatol (N Y). 2013 Jul;9(7):434-41.

17.

Changing donor characteristics in liver transplantation over the last 10 years in Canada.

Sela N, Croome KP, Chandok N, Marotta P, Wall W, Hernandez-Alejandro R.

Liver Transpl. 2013 Nov;19(11):1236-44. doi: 10.1002/lt.23718. Epub 2013 Oct 10.

18.

Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts.

Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R.

Liver Transpl. 2013 Nov;19(11):1214-23. doi: 10.1002/lt.23715. Epub 2013 Oct 10.

19.

Shedding light on a painful rash.

Al-Judaibi B, Chakrabarti S, Chandok N.

Arab J Gastroenterol. 2013 Jun;14(2):83-4. doi: 10.1016/j.ajg.2013.01.006. Epub 2013 Apr 2.

PMID:
23820507
20.

Recipient ineligibility after liver transplantation assessment: a single centre experience.

Arya A, Hernandez-Alejandro R, Marotta P, Uhanova J, Chandok N.

Can J Surg. 2013 Jun;56(3):E39-43. doi: 10.1503/cjs.004512.

21.

Pentoxifylline for slow to resolve hepatopulmonary syndrome post liver transplantation: helpful or unnecessary?

Aljudaibi B, Qumosani K, Chandok N.

Acta Gastroenterol Belg. 2013 Mar;76(1):70-1. No abstract available.

PMID:
23650789
22.

Early allograft dysfunction is associated with excess resource utilization after liver transplantation.

Croome KP, Hernandez-Alejandro R, Chandok N.

Transplant Proc. 2013 Jan-Feb;45(1):259-64. doi: 10.1016/j.transproceed.2012.07.147.

PMID:
23375312
23.

Polycystic liver disease: a clinical review.

Chandok N.

Ann Hepatol. 2012 Nov-Dec;11(6):819-26. Review.

24.

A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma.

Hernandez-Alejandro R, Croome KP, Drage M, Sela N, Parfitt J, Chandok N, Marotta P, Dale C, Wall W, Quan D.

World J Gastroenterol. 2012 Aug 21;18(31):4145-9. doi: 10.3748/wjg.v18.i31.4145.

25.

Representing complexity well: a story about teamwork, with implications for how we teach collaboration.

Lingard L, McDougall A, Levstik M, Chandok N, Spafford MM, Schryer C.

Med Educ. 2012 Sep;46(9):869-77. doi: 10.1111/j.1365-2923.2012.04339.x.

PMID:
22891907
26.

Burden of de novo malignancy in the liver transplant recipient.

Chandok N, Watt KD.

Liver Transpl. 2012 Nov;18(11):1277-89. doi: 10.1002/lt.23531. Epub 2012 Sep 26. Review.

27.

 Massive avascular malformations causing life threatening portal hypertension.

Arya A, Kakani N, Hussain N, Chandok N.

Ann Hepatol. 2012 Jul-Aug;11(4):552-3.

28.

Should a lower quality organ go to the least sick patient? Model for end-stage liver disease score and donor risk index as predictors of early allograft dysfunction.

Croome KP, Marotta P, Wall WJ, Dale C, Levstik MA, Chandok N, Hernandez-Alejandro R.

Transplant Proc. 2012 Jun;44(5):1303-6. doi: 10.1016/j.transproceed.2012.01.115.

PMID:
22664005
29.

Management of primary sclerosing cholangitis: conventions and controversies.

Chandok N, Hirschfield GM.

Can J Gastroenterol. 2012 May;26(5):261-8. Review.

30.

Causes of death after liver transplantation.

Nensi A, Chandok N.

Ann Hepatol. 2012 May-Jun;11(3):415-7. No abstract available.

31.

Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease.

Chandok N, Minuk G, Wengiel M, Uhanova J.

J Gastrointestin Liver Dis. 2012 Mar;21(1):53-8.

32.

Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension.

Chandok N, Kamath PS, Blei A, Bosch J, Carey W, Grace N, Kowdley KV, Benner K, Groszmann RJ.

Aliment Pharmacol Ther. 2012 Apr;35(8):904-12. doi: 10.1111/j.1365-2036.2012.05050.x. Epub 2012 Mar 1.

33.

Liver transplantation in older adults.

Nensi A, Chandok N.

J Am Geriatr Soc. 2012 Feb;60(2):400. doi: 10.1111/j.1532-5415.2011.03800.x. No abstract available.

PMID:
22332699
34.

Defining readmission risk factors for liver transplantation recipients.

Shankar N, Marotta P, Wall W, Albasheer M, Hernandez-Alejandro R, Chandok N.

Gastroenterol Hepatol (N Y). 2011 Sep;7(9):585-90.

35.

An unusual cause of cancer mimicry following liver transplantation.

Qumosani K, Chandok N.

Ann Hepatol. 2012 Jan-Feb;11(1):134-7.

36.

The impact of population-based screening studies on hemochromatosis screening practices.

Chandok N, Speechley M, Ainsworth PJ, Chakrabarti S, Adams PC.

Dig Dis Sci. 2012 May;57(5):1420-2. doi: 10.1007/s10620-011-2001-7.

PMID:
22160492
37.

Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Masyuk AI, Gradilone SA, Gajdos GB, Chandok N, Bakeberg JL, Ward CJ, Ritman EL, Kiyokawa H, LaRusso NF.

Gastroenterology. 2012 Mar;142(3):622-633.e4. doi: 10.1053/j.gastro.2011.11.036. Epub 2011 Dec 7.

38.

Do older patients utilize excess health care resources after liver transplantation?

Shankar N, AlBasheer M, Marotta P, Wall W, McAlister V, Chandok N.

Ann Hepatol. 2011 Oct-Dec;10(4):477-81.

39.

Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts.

Hernandez-Alejandro R, Croome KP, Quan D, Mawardi M, Chandok N, Dale C, McAlister V, Levstik MA, Wall W, Marotta P.

Transplantation. 2011 Sep 27;92(6):686-9. doi: 10.1097/TP.0b013e31822a79d2.

PMID:
21832962
40.

Elevated acetaminophen level: could it be a red herring?

Dale C, Denesyk KL, Chandok N.

Ann Hepatol. 2011 Apr-Jun;10(2):239-40. No abstract available.

41.

A pilot study of vitamin E for the treatment of cirrhotic muscle cramps.

Chandok N, Tan P, Uhanova J, Shankar N, Marotta P.

Liver Int. 2011 Apr;31(4):586-7. doi: 10.1111/j.1478-3231.2011.02464.x. Epub 2011 Feb 1. No abstract available.

PMID:
21382169
42.

The unfulfilled promise of efficacy trials in HIV/hepatitis C co-infected patients.

Chandok N, John S, Haider S.

Ann Hepatol. 2011 Jan-Mar;10(1):103-4. No abstract available.

43.

Clinical decision making in acute Budd Chiari Syndrome.

McKnight L, Chandok N, Hernandez-Alejandro R.

Ann Hepatol. 2010 Oct-Dec;9(4):473-4. No abstract available.

44.

Clinical outcomes of liver transplantation for polycystic liver disease: a single center experience.

Chandok N, Uhanova J, Marotta P.

Ann Hepatol. 2010 Jul-Sep;9(3):278-81.

45.

Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis.

Chandok N, Silveira MG, Lindor KD.

Gastroenterol Hepatol (N Y). 2010 Feb;6(2):108-12.

46.

Pain management in the cirrhotic patient: the clinical challenge.

Chandok N, Watt KD.

Mayo Clin Proc. 2010 May;85(5):451-8. doi: 10.4065/mcp.2009.0534. Epub 2010 Mar 31. Review.

47.

Working out the bug in the accordion.

Chandok N, Kamath PS.

Gastroenterology. 2009 Jul;137(1):e5-6. doi: 10.1053/j.gastro.2008.12.062. Epub 2009 Jun 6. No abstract available.

PMID:
19501204
48.

Effect of a nurse team coordinator on outcomes for hospitalized medicine patients.

Forster AJ, Clark HD, Menard A, Dupuis N, Chernish R, Chandok N, Khan A, Letourneau M, van Walraven C.

Am J Med. 2005 Oct;118(10):1148-53.

PMID:
16194647
49.

Adverse events among medical patients after discharge from hospital.

Forster AJ, Clark HD, Menard A, Dupuis N, Chernish R, Chandok N, Khan A, van Walraven C.

CMAJ. 2004 Feb 3;170(3):345-9. Erratum in: CMAJ. 2004 Mar 2;170(5):771.

Supplemental Content

Loading ...
Support Center